About BHV-1300
For patients with Graves’ disease, a significant unmet need exists for therapies treating the disease. To date, there is no approved medicine that targets the antibodies that cause the disease.
BHV-1300 is a novel small molecule that has the potential to target the disease at its core, stopping the symptoms.
Administration of the Study Medication
The study medication will be administered by injection (subcutaneously).